Completed PHASE2 INTERVENTIONAL 2-arm NCT01607294

A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

Sponsor: Esperion Therapeutics, Inc.

Conditions Hyperlipidemia Type 2 Diabetes

Interventions ETC-1002 Placebo

Updated 9 times since 2017 Last updated: Mar 26, 2019 Started: Apr 30, 2012 Primary completion: Oct 31, 2012 Completion: Oct 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01607294, this PHASE2 trial focuses on Hyperlipidemia and Type 2 Diabetes and remains completed. Sponsored by Esperion Therapeutics, Inc., it has been updated 9 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Feb 2021 — Apr 2022 [monthly]

Completed PHASE2
Jan 2021 — Feb 2021 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Apr 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Apr 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Esperion Therapeutics, Inc.

Data source: Esperion Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miramar, United States